How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing
Citeline’s Pang Suggests Diverse Business Models For Korean Biopharma
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
